Kymera Therapeutics Inc — Quarterly Financial Statistics (NASDAQ:KYMR) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Dividends

Quarterly Annual

Cash from operating activities 50.19 M61.78 M79.15 M59.88 M27.11 M66.75 M 232.89 M Cash from investing activities 157.68 M-68.57 M48.62 M60.02 M18.03 M394.4 M 521.06 M Cash from financing activities 250.92 M2.77 M258 K245.73 M39.51 M705.22 M 990.71 M Free cash flow 50.38 M60.85 M78.68 M59.19 M26.93 M66.64 M 231.44 M

News

Kymera Q4 Loss Wider Than Expected, Cash Boost Extends Runway

Morgan Stanley cuts Kymera Therapeutics stock price target on pipeline progress

RBC Capital raises Kymera Therapeutics price target on pipeline progress

RBC Capital raises Kymera Therapeutics price target on pipeline

Stifel reiterates Buy rating on Kymera Therapeutics stock at $114

Kymera Q4 2025 slides: pipeline advances despite revenue miss

Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates

Kymera Therapeutics launches $500 million at-the-market stock offering

Kymera earnings missed by $0.18, revenue fell short of estimates

Kymera Therapeutics CEO Nello Mainolfi sells $2.7 million in shares

Kymera Therapeutics: The More This Biotech Spends, The Higher Its Valuation Rises (KYMR)

Kymera earnings up next as protein degrader rally faces catalyst test